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ABSTRACT
A heterologous system that enables rapid screening of the principal routes of 
metabolism of drugs, herbs, food and new chemical entities (NCE) would be of 
enormous benefit in research and drug development. Cytochrome P450 (CYP) 2C9 is 
one of the principal enzymes involved in the metabolism of many drugs such as 
phenytoin, warfarin, tolbutamide, celecoxib, fluoxetine and losartan. However, to date 
its roles in the clearance of other compounds such as local herbs Eurycoma longifolia 
Jack (Tongkat Ali) have not been reported. An inM tro  heterologous enzyme system 
was developed using E. coli (DH5a) to study the metabolism of these compounds. 
Recombinant CYP2C9 and NADPH-Cytochrome P450 reductase were co-expressed in 
separate but compatible plasmid to generate an active in-vitro drug metabolizing system. 
The yield of the protein expressed was at the optimum level when the culture were 
incubated at 30°C and harvested after 24 hour. Immunoblotting demonstrated the 
presence of both CYP2C9 and reductase protein with sizes approximately 55 kDa and 
80 kDa respectively. The kinetic activity of the enzyme was characterized using 
fluorescent base Vivid® CYP450 Screening Kit. Incubation of enzymes with different 
concentration of BOMCC substrate was done to determine the kinetic parameters ( V max 
= 64.1 nM, Km = 99.1 pM). Assay between CYP2C9-Eurycoma longifolia Jack 
(Tongkat Ali) was carried out to study the possibility of the inhibition effect of Tongkat 
Ali towards the enzyme. Presence of 20 pg and 50 pg Tongkat Ali in the reaction 
showed reduced enzyme activity. Higher concentration of Tongkat Ali gave higher 
inhibition, thus lowering the velocity of enzyme in which its k, value is 5408.9 pM. The 
result of this study contributes in enhancing the drug-herb interaction database profile 
on the metabolism pathway and inhibitory effects of local herbs towards CYP2C9.
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Cytochrome P450 (CYP450) comprises a superfamily of homeoproteins, which 
functions as the terminal oxidase of the mixed function oxidase system. This 
superfamily is divided into families and further subdivided into subfamilies according 
to their amino acid sequences (Nelson et. al, 1996). In human, the most important CYPs 
in drug metabolism are CYP2A6, CYP2C9, CYP2C19, CYP2D6 and CYP2E1 
(Taavitsainen, 2001) but the expression of CYP enzymes varies between individuals 
due to some factors including genetics, environmental or some diseases (Rendic, 2002). 
These variations will lead to inter -  individual pharmacokinetics and pharmacodynamics 
of drugs variations (Miners et. al, 1998).
Several methods have been used to study human drug metabolism, for example 
by using human liver microsomes or homogenates, and hepatocytes cultures. However, 
the first two methods have its own limitations as* i) it is difficult to get donation of 
human liver; ii) presence of a variety of CYPs in human liver; iii) most of the CYPs 
have similar structure and amino acid sequence hence causing difficulties in identifying 
specific CYPs which is responsible for the metabolism of a particular drug, and lastly; 
iv) level of CYPs vary throughout the population and will contribute to assay errors in 
the study. The introduction of heterologous expression system has managed to
